How ACA Risk Adjustment Data Validation can affect financial results, operational strategy, and long-term risk adjustment performance
ACA Risk Adjustment Data Validation (RADV) is not simply a regulatory audit. It is a multiyear financial and operational process that can materially affect risk adjustment transfers, profitability, accruals, pricing assumptions, and business planning.
Download Wakely’s white paper to understand how ACA RADV works, what is changing for benefit year 2025, and how issuers can build a more proactive approach to managing RADV exposure.
DOWNLOAD NOWWhat you’ll learn
This report provides practical, issuer-focused insight into:
- Why ACA RADV has a multiyear financial impact
- How RADV results can affect risk adjustment transfers and profitability
- What the 2025 sampling methodology changes mean for issuers
- Why historical RADV performance may not be a reliable predictor of future results
- How documentation, coding, chart retrieval, provider collaboration, and audit operations influence outcomes
- What issuers should consider when forecasting RADV impacts and setting accruals
- How to evaluate whether current RADV operations are scalable and sustainable
RADV results can affect financial performance years after the benefit year
CMS releases final RADV results approximately two years after the applicable benefit year. This creates a significant gap between when issuers recognize risk adjustment estimates and when final RADV impacts are known and settled.
The financial consequences can be meaningful. In 2024, 30 individual ACA markets and 28 small group ACA markets experienced a RADV adjustment. Among individual issuers in markets identified as outliers, approximately 1.6% experienced an unfavorable adjustment of at least 2% of premium. In extreme cases, the impact can be substantially larger.
These delayed results make RADV an important consideration for financial forecasting, pricing, accruals, and enterprise risk management.
Benefit year 2025 brings important changes
Beginning with benefit year 2025, CMS is implementing changes that may affect both RADV sampling and issuer operations:
- Members without an HCC will be excluded from the RADV sample.
- CMS will use three years of HHS-RADV data for the Neyman allocation methodology.
- Smaller issuers may be subject to a sample of up to 200 members with HCCs—or all members with HCCs if the issuer has fewer than 200.
These changes may alter the composition and size of audit samples, operational workload, national benchmarks, and confidence intervals. Issuers should evaluate whether existing processes are sufficient for the evolving RADV environment.
Key questions for ACA issuers
A strong RADV strategy begins well before the audit. Issuers should consider:
- Do we have a dedicated team responsible for ACA RADV?
- Is our approach designed specifically for ACA RADV?
- Are coding, documentation, chart retrieval, and provider engagement connected throughout the risk adjustment cycle?
- Are we reviewing and addressing documentation gaps before they become RADV findings?
- Are we monitoring performance by low-, medium-, and high-HCC groupings?
- How are RADV assumptions reflected in forecasts, accruals, and pricing?
- Is our operating model scalable as membership grows?
- Are we using prior RADV results to make measurable operational improvements?
- Are we prepared for future CMS methodology and regulatory changes?
How Wakely can help
Wakely supports issuers across the risk adjustment lifecycle, including ACA RADV exposure estimation, RADV-readiness assessments, operational reviews, team training, accrual support, audit oversight, and sustainable process improvement.
Wakely clients participating in the Wakely National Risk Adjustment Reporting project may receive estimated RADV results before CMS releases official results, supporting earlier financial planning and strategic decision-making.
